Please login to the form below

Not currently logged in
Email:
Password:

Nycomed/Almirall sign China deal

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall’s antihistamine Kestine (ebastine) in China and other markets in Southeast Asia

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall's antihistamine Kestine (ebastine) in China and other markets in Southeast Asia.

As part of the deal, Nycomed will hold exclusive commercialisation rights for Kestine in China, where the product is already available, as well as rights for the drug once it is launched in Malaysia, Philippines, Singapore, Thailand and Indonesia.

Kestine, prescribed for the treatment of allergic rhinitis and chronic idiopathic urticaria, is already approved for marketing in 30 countries.
Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice president, Commercial Operations at Nycomed explained the deal would support the company's development in Asia.

He said: "Emerging markets continue to be our focus area for future growth."

29th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics